<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477527</url>
  </required_header>
  <id_info>
    <org_study_id>EB001JP001</org_study_id>
    <nct_id>NCT02477527</nct_id>
  </id_info>
  <brief_title>Atripla to Stribild Switch Study to Evaluate Sleep Disturbances</brief_title>
  <official_title>Switching From Atripla to Stribild Leads to Improvements in Central Nervous System Side Effects and Sleep Disturbances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midtown Medical Center, Tampa, FL</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Midtown Medical Center, Tampa, FL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Switch patients from Atripla to Stribild will be evaluated to see if patients have less
      sleep disturbances.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stribild is a preferred regimen in the Department of Health and Human Services guidelines
      and has demonstrated non-inferiority to Atripla in treatment na√Øve patients out to 144 weeks
      (GS-102). Stribild also has statistically significant less Central Nervous System side
      effects, sleep disturbances and lipid elevations compared to Atripla. This study will
      evaluate the efficacy, safety, changes in Central Nervous System abnormalities and sleep
      disorders following a switch from virologically suppressed subjects on Atripla to Stribild.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with viral loads &lt; 50 following the switch</measure>
    <time_frame>24 weeks</time_frame>
    <description>blood measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell changes</measure>
    <time_frame>24 weeks</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvements in Central Nervous System toxicity score</measure>
    <time_frame>24 weeks</time_frame>
    <description>questionnaire evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvements in sleep disorder score</measure>
    <time_frame>24 weeks</time_frame>
    <description>questionnaire evaluation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety as measured by side effects</measure>
    <time_frame>24 weeks</time_frame>
    <description>Monitor for any side effects</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>Stribild</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil</intervention_name>
    <description>Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.</description>
    <arm_group_label>Stribild</arm_group_label>
    <other_name>Stribild</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+ subjects 18 years of age or older

          -  estimated Glomerular Filtration Rate &gt; 70 mL/min

          -  must currently be on Atripla and taking it for at least 3 months with a HIV-1 Viral
             Load &lt; 50 copies/mL

          -  no antiretrovirals prior to the initiation of Atripla

          -  baseline genotyping

        Exclusion Criteria:

          -  pregnancy

          -  unable to provide informed consent

          -  enrolled in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward W Braun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midtown Medical Center</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 21, 2016</lastchanged_date>
  <firstreceived_date>June 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atripla</keyword>
  <keyword>stribild</keyword>
  <keyword>dreams</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
